Heron Therapeutics | HRTX - Pre Tax Profit


Heron Therapeutics reported $-2.95M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
ALKERMES USD -61.93M 122.3M Mar/2026
Alnylam Pharmaceuticals USD 177.81M 43.85M Jun/2026
Amarin USD -852K 7.26M Dec/2025
ANI Pharmaceuticals USD 40.22M 8.74M Mar/2026
Anika Therapeutics USD 764K 3M Dec/2025
Arrowhead Research USD -178.9M 41.34M Jun/2026
Eisai JPY 25.28B 33.22B Jun/2026
GlaxoSmithKline GBP 2.68B 532M Jun/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -11.37M 150.72M Jun/2026
Ligand Pharmaceuticals USD -24.26M 81.04M Mar/2026
Merck USD -3.53B 6.95B Mar/2026
Nektar Therapeutics USD -43.09M 8.39M Mar/2026
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Omeros USD -65.12M 21.27M Jun/2024
Pacira USD 5M 4.43M Mar/2026
Regeneron Pharmaceuticals USD 1.53B 696.6M Jun/2026
Roche Holding CHF 11.17B 6.38B Jun/2026
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Ultragenyx Pharmaceutical USD -91M 93M Jun/2026
Veracyte USD 26.52M 3.45M Jun/2026
Vertex Pharmaceuticals USD 1.39B 138.9M Jun/2026